Cancer

Plasma cell-free DNA markers predict occult metastases in patients with resectable pancreatic ductal adenocarcinoma

Jacob E. Till, Ofer Gal-Rosenberg, Sophia G. Giliberto, Nicholas J. Seewald, Dominique Ballinger, Heather E. Samberg, Melinda R. Yin, Qiao-Li Wang, Samuele Cannas, Kristine N. Kim, Kyle Tien, Mohammed Sawi, Vidya Madineedi, C. Sloane Furniss, Vasilena Gocheva, Jonathan Nowak, Lauren K. Brais, Chen Yuan, Michael H. Rosenthal, Robert Roses, Ronald DeMatteo, Major Kenneth Lee, Chrles Vollmer, Hersh Sagreiya, Mark H. O'Hara, Ruth Shemer, Brian Wolpin, Yuval Dor, Erica L. Carpenter

LODESTAR: A single arm phase II study of rucaparib in solid tumors with pathogenic germline or somatic variants in homologous recombination repair genes

Purpose: To explore PARP inhibitor (PARPi) utility across solid tumors and identify biomarkers that predict sensitivity.

Patients and …

Sriram Anbil, Nicholas J. Seewald, E. Gabriela Chiorean, Maen Hussein, Pashtoon Murtaza Kasi, Doug E. Laux, Gary K. Schwartz, Geoffrey Shapiro, Kevin K. Lin, Marcia Craib, Lara Maloney, Karen McLachlan, Hanna Tukachinsky, Alexa B. Schrock, Shuoguo Wang, Ethan S. Sokol, Brennan Decker, Katherine L. Nathanson, Susan M. Domchek, Kim A. Reiss

[Abstract] Circulating tumor DNA (ctDNA), dormant disseminated tumor cells (DTCs) and recurrence outcomes in breast cancer survivors on the SURMOUNT Study

Background: Recurrence after early-stage breast cancer (BC) is a challenge, occurring in ∼30% of patients (pts). Recurrences may arise …

Eleanor Taranto, Nicholas J. Seewald, Lauren J. Bayne, Emma Walinsky, Shannon Deluca, Natalie NC. Shih, Pauleen Sanchez, Isoris Nivar, Bana Ambasager, Clodagh Murray, Amber Chevalier, Christopher G. Smith, Igor Makhlin, Killian Rohn, Brooke L. Goodspeed, Jessica Savage, Paul Wileyto, Jianping Wang, George Belka, Elizabeth Chislock, Lindsay R Berry, Don Berry, Anupma Nayak, Michael Feldman, Amy S. Clark, Lewis A. Chodosh, Angela DeMichele

Patient-Reported Outcomes in Cancer

Patient-centered care is an important aspect of treating cancer, particularly as a way to inform comparative effectiveness research. This work builds an evidence base for treatment selection based on quality of life and other measures.

Cancer Biomarkers and Pharmacogenomics

A series of collaborations with cancer researchers at the University of Pennsylvania and the University of Michigan investigating associations between biomarkers, genes, tumor morphology, and outcomes.

Corticosteroid-dependent association between prognostic peripheral blood cell-free DNA levels and neutrophil-mediated NETosis in patients with glioblastoma

Purpose: Non-invasive prognostic biomarkers to inform clinical decision-making are an urgent unmet need for the management of patients …

Jacob E. Till, Nicholas J. Seewald, Zachariya Yazdani, Zhuoyang Wang, Dominique Ballinger, Heather Samberg, Siri Dandu, Camilla Macia, Melinda Yin, Aseel Abdalla, Timothy Prior, Shivani Shah, Thara Patel, Emily McCoy, Maikel Monsour, Carson A. Wills, Veronica Bochenek, Jonathan Serrano, Matija Snuderl, Richard E. Phillips, Donald M. O’Rourke, Nduka M. Amankulor, Ali Nabavizadeh, Arati S. Desai, Kandace Gollomp, Zev A. Binder, Wanding Zhou, Stephen J. Bagley, Erica L. Carpenter

[Abstract] Real-world time on treatment (rwTOT) with first-line (1L) enfortumab vedotin and pembrolizumab (EV+P) after U.S. Food and Drug Administration approval for advanced urothelial cancer (aUC)

ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium

Melanie Mayer, Nicholas J. Seewald, Ernesto Ulloa Perez, Blanca Homet Moreno, Chethan Ramamurthy, Aram Babcock, Haojie Li, Ronac Mamtani

[Abstract] Does liver tumor morphology predict outcomes after LDT, PRRT or captem?

Background: Patients with metastatic neuroendocrine tumor (NET) have multiple options for liver-directed therapy (LDT) and systemic …

Cathal O'Leary, David Tischfield, Rony Avritscher, Ghassan El-Haddad, Nicholas Fidelman, Ricardo Garcia-Monaco, Nimrata Vijayvergia, Pamela Kunz, Nicholas J. Seewald, Michael C. Soulen

[Abstract] LODESTAR: A Single Arm Phase II Study of Rucaparib in Solid Tumors with Pathogenic Germline or Somatic Variants in Homologous Recombination Repair (HRR) Genes

Purpose: Poly (ADP-ribose) polymerase inhibitors (PARPi) have proven clinical utility in platinum-sensitive breast, ovary, pancreas, …

Sriram Anbil, Nicholas J. Seewald, Kevin Lin, Marcia Craib, Christy Connor, Heidi Giordano, Karen McLachlan, Tanya Kwan, Lara Maloney, Hanna Tukachinsky, Alexa Schrock, Shuoguo Wang, Ethan Sokol, Brennan Decker, Katherine Nathanson, Susan Domchek, Kim Reiss

[Abstract] Association of BRCA1/2 pathogenic variants with primary tumor location and metastatic organotropism in pancreatic adenocarcinoma

Background: Pancreatic cancers (PDACs) with BRCA1/2 pathogenic variants (PVs) are prognostically favorable and predict response to …

Ryan Hood, Srishti Rathore, Nicholas J. Seewald, Kim Anna Reiss